Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
about
lncRNA/MicroRNA interactions in the vasculatureIn vivo interrogation of the molecular display of atherosclerotic lesion surfaces.Matrix metalloproteinase-9 as new biomarkers of severity in multiple organ dysfunction syndrome caused by trauma and infection.Decreased fibrocyte number is associated with atherosclerotic plaque instability in man.Molecular imaging in cancer treatment.The role of matrix degrading enzymes and apoptosis in rupture of membranes.The role of matrix metalloproteinases (MMPs) in human caries.Matrix metalloproteinases and atherogenesis in dependence of age.Mast cells in vulnerable atherosclerotic plaques--a view to a kill.Green tea catechins and cardiovascular health: an update.MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factorsVascular smooth muscle cell in atherosclerosis.p66Shc deletion confers vascular protection in advanced atherosclerosis in hypercholesterolemic apolipoprotein E knockout mice.2,3,4',5-Tetrahydroxystilbene-2-O-beta-D-glucoside suppresses matrix metalloproteinase expression and inflammation in atherosclerotic rats.Alterations in matrix metalloproteinase-9 levels and tissue inhibitor of matrix metalloproteinases-1 expression in a transforming growth factor-beta transgenic model of hydrocephalus.
P2860
Q26766577-309487D9-2136-4FA9-B2A3-EE35BAB65E3DQ31017247-AF5CD675-356E-46E0-AEBA-7E02056D01B9Q34037194-B27D4624-908A-4F9E-99DA-38EE48F93376Q34250211-37E6913F-A270-4D6D-8A1D-83E02D556A20Q34496670-7E3B5A45-031C-4B2D-85AC-B7C04F9D684EQ35905679-AB8C4A3A-0320-4A2B-B301-D7E51E0AC9FDQ36350978-6EB65813-F2EA-4BE0-8562-5077D58E265EQ36626394-05574963-DB85-4BA0-8832-469CEFDF91F6Q36924398-5D3FDDDD-3B6A-4005-9C54-95A77F2E02B2Q37239682-03B7411C-3CFA-4478-802C-39A9F8F23D18Q37600292-B020CFD5-8AEE-4DDA-97F0-738F52E55489Q38353932-03EE35CA-B477-4A86-9F42-46270848C896Q46147613-FEA20D8B-ADE7-404F-B6F3-1A1692E09824Q46921380-9F706442-EA0D-4ECC-9EC5-AAE959644106Q48494187-4FF41444-FD74-4FF6-8DC1-CDEA2E07B7F3
P2860
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
name
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@ast
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@en
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@nl
type
label
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@ast
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@en
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@nl
prefLabel
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@ast
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@en
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@nl
P2860
P356
P1476
Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
@en
P2093
P2860
P304
P356
10.1517/13543784.9.5.993
P407
P577
2000-05-01T00:00:00Z